How GlaxoSmithKline Lost Nearly $10B in October Post author:Sam Post published:November 9, 2017 Post category:BioPharma Could GlaxoSmithKline’s industry-leading dividend be at risk? Source: BioSpace You Might Also Like Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease August 2, 2017 Mayne Pharma Appoints Executive Vice President at Metrics Contract Services July 18, 2017 Hill-Rom To Host Fiscal Fourth Quarter 2017 Earnings Conference Call And Webcast September 28, 2017
Johnson & Johnson's Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease August 2, 2017
